Funder
The University of Queensland
Publisher
Springer Science and Business Media LLC
Reference116 articles.
1. Dylst P, Vulto A, Simoens S. Societal value of generic medicines beyond cost-saving through reduced prices. Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):701–11.
2. Modena V, Bianchi G, Roccatello D. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target? Autoimmun Rev. 2013;12(8):835–8.
3. Government A. Trans-Pacific Partnership Agreement - Outcomes: Biologics, F.A.a. Trade, Editor. 2016, Australian Government: Australia.
4. (EMA), E.M.A. Biosimilar medicines can be interchanged. 2022, European Medicines Agency.
5. Chaplin S. Biosimilars in the EU: a new guide for health professionals. Prescriber (London, England). 2017;28(10):27–31.